News from mallinckrodt plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

31 Aug, 2020, 07:02 BST Mallinckrodt Announces 2020 Investigator Award to Further Advances in ECP Immunomodulation

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the recipient of 2020's Advancing Extracorporeal Photopheresis...


08 Nov, 2019, 11:45 GMT Mallinckrodt to Present at Jefferies London Healthcare Conference

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present at the Jefferies London Healthcare Conference in London on Wednesday,...


05 Apr, 2019, 07:00 BST Mallinckrodt Announces Study Demonstrating Effectiveness of ECP Immunomodulation, as an adjunct to local standard therapy, in Treatment of Lung Transplant Patients with Bronchiolitis Obliterans Syndrome (BOS)

Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announces the presentation of a retrospective study that demonstrates the...


25 Feb, 2019, 14:00 GMT Mallinckrodt Announces Extracorporeal Photopheresis (ECP) Research Collaboration Agreement With Transimmune AG

Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today announced it has entered into a research collaboration...


21 Feb, 2019, 08:00 GMT Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today announced interim analysis results of its company-sponsored,...


17 Sep, 2018, 19:00 BST Mallinckrodt Announces Donation of Two Transport Vehicles to Coolmine Therapeutic Community (TC)

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced a donation to Coolmine Therapeutic Community...


20 Mar, 2018, 08:00 GMT Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation

€50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical...


28 Oct, 2016, 08:00 BST Mallinckrodt Builds UK Presence With New Global Corporate Headquarters in Staines-upon-Thames

Company Announces £100,000 Donation to Local NHS Trust Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, has announced that...